<DOC>
	<DOCNO>NCT02014480</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , 3-way crossover study evaluate lung function response UMEC 62.5 mcg , VI 25 mcg , UMEC/VI 62.525 mcg , administer once-daily via novel dry powder inhaler ( NDPI ) 14 day subject COPD . The study consist Run Phase ( 5 7 day ) , Treatment Phase ( make 3 treatment period 14 day separate 10 14 day Washout Period ) Follow-up Phase ( 7 9 day completion final visit premature discontinuation ) . Eligible subject randomize sequence UMEC 62.5 mcg , VI 25 mcg , UMEC/VI 62.5/25 mcg subject receive treatment . Serial spirometry assessment conduct Day 1 Day 14 trough spirometry conduct Day 2 Day 15 treatment period . On Day 1 14 treatment period vital sign assess adverse event ( AE ) record throughout total duration study ( approximately 12 week ) .</brief_summary>
	<brief_title>A Cross-Over Study Evaluate Lung Function Response After Treatment With Umeclidinium ( UMEC ) 62.5 Micrograms ( mcg ) , Vilanterol ( VI ) 25 mcg , Umeclidinium/Vilanterol ( UMEC/VI ) 62.5/25 mcg Once-Daily Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Type Patient : Outpatient . Informed Consent : A sign date write informed consent prior study participation . Age : Subjects 40 year age old Visit 1 . Gender : Male female subject . A female eligible enter participate study : Nonchild bear potential . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g . age appropriate , &gt; 45 year , absence hormone replacement therapy . OR Child bear potential , negative pregnancy test screening , agree one acceptable contraceptive method use consistently correctly . Diagnosis : An established clinical history COPD accordance definition American Thoracic Society/European Respiratory Society . Smoking History : Current former cigarette smoker history cigarette smoke &gt; = 10 packyears Visit 1 . Severity Disease : A pre postsalbutamol FEV1/forced vital capacity ( FVC ) ratio &lt; 0.70 pre postsalbutamol FEV1 &lt; =70 % predict normal value Visit 1 calculated use Nutrition Health Examination Survey ( NHANES ) III reference Equations . Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : A current diagnosis asthma . Other Respiratory Disorders : Known alpha1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . A subject , , opinion investigator , significant respiratory condition addition COPD , exclude . Examples may include clinically significant bronchiectasis , pulmonary hypertension , sarcoidosis , interstitial lung disease . Allergic rhinitis exclusionary . Other Diseases/Abnormalities : Subjects historical current evidence clinically significant cardiovascular , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled and/or previous history cancer remission &lt; 5 year prior Visit 1 ( localize carcinoma skin resect cure exclusionary ) . Contraindications : A history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , lactose/milk protein magnesium stearate medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , opinion study physician contraindicates study participation use inhale anticholinergic . Hospitalization : Hospitalization COPD pneumonia within 12 week prior Visit 1 . Lung Resection : Subjects lung volume reduction surgery within 12 month prior Visit 1 . 12Lead ECG : An abnormal significant electrocardiogram ( ECG ) find 12lead ECG conduct Visit 1 , Investigators provide ECG review conduct centralized independent cardiologist assist evaluation subject eligibility . The study investigator determine medical significance ECG abnormality . Medication Prior Spirometry : Unable withhold salbutamol 4 hour period require prior spirometry test study visit spirometry test perform home . Medications Prior Screening : Use follow medication accord follow defined time interval prior Visit 1 : Depot corticosteroid ( 12 week ) , oral parenteral corticosteroid ( 6 week ) , antibiotic ( low respiratory tract infection ) ( 6 week ) , cytochrome P450 3A4 strong inhibitors2 ( 6 week ) , longacting beta agonist ( LABA ) / inhale corticosteroid ( ICS ) combination product LABA/ICS therapy discontinue completely ( 30 day ) , use ICS dose &gt; 1000 mcg/day fluticasone propionate equivalent ( 30 day ) , initiation discontinuation ICS use ( 30 day ) , tiotropium ( 7 day ) , roflumilast ( 14 day ) , theophylline ( 48 hour ) , oral leukotriene inhibitor ( zafirlukast , montelukast , zileuton ) ( 48 hour ) , oral betaagonists longacting ( 48 hour ) , shortacting ( 12 hour ) , inhale long act beta2agonists ( LABA , e.g. , salmeterol , formoterol , indacaterol ) ( 48 hour ) , LABA/ICS combination product discontinue LABA therapy switch ICS monotherapy ( 48 hour LABA component ) , inhaled sodium cromoglycate nedocromil sodium ( 24 hour ) , inhale short act beta2agonists ( 4 hour ) , inhale shortacting anticholinergic/shortacting beta2agonist combination product ( 4 hour ) investigational medication 30 day within 5 drug halflives ( whichever longer ) . Oxygen : Use longterm oxygen therapy ( LTOT ) describe oxygen therapy prescribe great 12 hour day . Asneeded oxygen use ( i.e. , &lt; =12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , salbutamol , ipratropium bromide ) via nebulized therapy . Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 . Subjects maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : Is investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member aforementioned involve study . Inability read : In opinion Investigator , subject unable read and/or would able complete questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Long-acting beta-agonist</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Umeclidinium</keyword>
	<keyword>Long-acting muscarinic antagonist</keyword>
	<keyword>Vilanterol</keyword>
</DOC>